福安药业28个药品拟中选集采，股价近期震荡下行

Group 1 - The core viewpoint of the articles highlights that Fu'an Pharmaceutical's subsidiary has 28 drug varieties selected for the national centralized procurement, which includes products like dexmedetomidine, apixaban, and quetiapine, covering areas such as anti-infection, psychiatric, and anesthetic fields [1] - The total sales for these products are projected to be approximately 680 million yuan for 2024, accounting for 28.43% of the company's revenue, and about 329 million yuan for the first three quarters of 2025, representing 25.05% of revenue [1] - The procurement period extends until December 31, 2028, which is expected to stabilize the company's centralized procurement base, although there is a need to monitor potential pressure on gross margins due to price declines [1] Group 2 - In the recent trading period, Fu'an Pharmaceutical's stock price has shown a downward trend, with a cumulative decline of 1.12% over the last seven trading days and a price fluctuation of 4.20% [2] - As of February 13, the stock price closed at 4.40 yuan, with a turnover rate of 0.50% and a transaction amount of 21.35 million yuan; there was a net outflow of main funds, with a single-day net outflow of 13.01 million yuan on February 12, accounting for 20.43% of the transaction amount [2] - The technical indicators suggest that the stock price is currently near the lower band of the 20-day Bollinger Bands, and the MACD indicator indicates a weak short-term trend, with the pharmaceutical and biotechnology sector declining by 0.32%, showing that the company's stock performance is slightly weaker than the industry average [2]